These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 2878201)

  • 1. Co-dergocrine.
    Krupp P; Loew DM
    Lancet; 1986 Dec; 2(8519):1335. PubMed ID: 2878201
    [No Abstract]   [Full Text] [Related]  

  • 2. Influence of co-dergocrine on platelet aggregation.
    Santos RO; Rodrigues R
    Braz J Med Biol Res; 1990; 23(3-4):325-7. PubMed ID: 2094545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-dergocrine plasma concentrations and blood pressure changes in hypertensive patients during therapy with slow-release co-dergocrine mesylate.
    Woodcock BG; Herrmann W; Habedank WD
    Int J Clin Pharmacol Ther Toxicol; 1992 Feb; 30(2):63-5. PubMed ID: 1551748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the cardiovascular effects of co-derocrine (Hydergine).
    Clark BJ; Bucher T; Waite R
    J Pharmacol; 1985; 16 Suppl 3():101-11. PubMed ID: 2869189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of co-dergocrine mesylate on catecholamines and prolactin in elderly hypertensive patients].
    Mies R; Lang R; Weidinger G; Welzel D
    Arzneimittelforschung; 1983; 33(5):771-3. PubMed ID: 6683557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal and antihypertensive effects of co-dergocrine (Hydergine) in rats.
    Siegl H
    J Pharmacol; 1985; 16 Suppl 3():113-27. PubMed ID: 3912625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of asthmatic patients using an alpha-adrenergic receptor blocking agent, co-dergocrine mesylate ('Hydergine').
    Kitamura S
    Pharmatherapeutica; 1980; 2(5):330-6. PubMed ID: 7433473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability of slow-release co-dergocrine mesylate (dihydroergotoxine) formulations.
    Woodcock BG; Habedank WD; Loh W; Herrmann W; Rietbrock N
    Int J Clin Pharmacol Ther Toxicol; 1987 Dec; 25(12):660-3. PubMed ID: 3436686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A long-term study with co-dergocrine mesylate (Hydergine) in healthy pensioners. Results after 3 years.
    Köberle S; Spiegel R
    Gerontology; 1984; 30 Suppl 1():3-52. PubMed ID: 6489764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of co-dergocrine mesilate/nifedipine compared to mefruside/nifedipine on circadian blood pressure in patients with essential hypertension.
    Kirsten R; Heller A; Heintz B; Nelson K
    J Hum Hypertens; 1990 Aug; 4(4):461-4. PubMed ID: 2258894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of co-dergocrine on cyclosporin A pharmacokinetics and pharmacodynamics.
    Heinrichs DA; Martell R; Stiller CR; Freeman D; Carruthers G
    Br J Clin Pharmacol; 1987 Jul; 24(1):117-8. PubMed ID: 3497660
    [No Abstract]   [Full Text] [Related]  

  • 12. Co-dergocrine mesylate (Hydergine) and hypertensive emergencies.
    Romero R; Felip A; Llibre JM; Bonet J; Caralps A
    Nephron; 1989; 51(1):127-8. PubMed ID: 2915745
    [No Abstract]   [Full Text] [Related]  

  • 13. Phosphorylation of myelin basic proteins: an age-dependent process affected by divalent cations and Co-Dergocrine (dihydroergotoxine).
    Hiestand PC; Poschmann G; Zihlmann HR
    Exp Aging Res; 1983; 9(1):9-15. PubMed ID: 6190658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Letter: "Happy death day".
    Cohen C
    Br Med J; 1975 Dec; 4(5996):581. PubMed ID: 812583
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of dihydroergotoxine (Redergine) on the sleep-wakefulness cycle in the cat.
    Susić V; Masirević G
    Gerontology; 1979; 25(4):212-8. PubMed ID: 222649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebral glucose metabolism in aging rodents: effects of co-dergocrine.
    London ED; Walovitch RC
    J Pharmacol; 1985; 16 Suppl 3():73-84. PubMed ID: 4094450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ergoloid mesylates vs. Alzheimer's: the latest round.
    Walker C
    Geriatrics; 1990 Dec; 45(12):22, 24. PubMed ID: 2253892
    [No Abstract]   [Full Text] [Related]  

  • 18. Sinus bradycardia following treatment with hydergine for cerebrovascular insufficiency.
    Dcayley AC; Macpherson A; Wedgwood J
    Br Med J; 1975 Nov; 4(5993):384-5. PubMed ID: 811310
    [No Abstract]   [Full Text] [Related]  

  • 19. Dihydroergocristine-induced retroperitoneal fibrosis with an episode of reversible obstructive acute renal failure.
    Campieri C; Orsi C; De Giovanni P; Giudicissi A; La Manna G; Sestigiani E; Di Grazia A; Rimondi MR; Battaglia M; Zompatori M
    Nephron; 1995; 69(2):184-5. PubMed ID: 7723911
    [No Abstract]   [Full Text] [Related]  

  • 20. [The action of dihydroergotoxine in acute sickling crisis. Results of a double-blind study carried out in French speaking Africa (author's transl)].
    Begue P; Bertrand E; Bonhomme J; David M; Coullet Y; Pierredon M; Sankale M
    Nouv Presse Med; 1978 Aug 26-Sep 2; 7(28):2449-52. PubMed ID: 358140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.